{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Overall response rate is the best response of complete response (CR) or partial response (PR) as classified by the independent central review according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants per cohort with at least 1 measurable lesion, multiplied by 100.","groups":[{"description":"Participants received 10 mg dose of LY3435151 via intravenous (IV) as an IV push or IV bolus infusion.","id":"OG000","title":"10 mg LY3435151"}],"populationDescription":"Zero participants were analyzed. The study was terminated early and no data was collected.","reportingStatus":"POSTED","timeFrame":"Baseline through Disease Progression or Death (Up to 4 Months)","title":"Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR)","type":"SECONDARY"}